title: Acquired circulating anticoagulants.
abstract: Acquired inhibitors of blood coagulation, which are pathologic circulating substances that directly inhibit clotting factors or their reactions, most commonly occur in patients with hereditary bleeding disorders. This article contains a discussion of acquired circulating anticoagulants that arise de novo in patients with previously normal hemostatic mechanisms. Pathogenesis and management are also discussed. Treatment of these patients poses a challenge for the hematologist because, unlike hereditary hemophiliacs who have learned to adjust their lifestyle, the acquired hemophiliac is unprepared for hemorrhagic episodes.
authors.affiliation: Department of Medicine, University of California, School of Medicine, Los Angeles.
authors.forename: L A
authors.initials: LA
authors.lastname: Kunkel
mesh_terms: D001323:Autoantibodies / Q000097:blood*; D001778:Blood Coagulation Disorders / Q000276:immunology*; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors* / Q000276:immunology; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D016682:Lupus Coagulation Inhibitor
chemical_list: D001323:Autoantibodies; D001779:Blood Coagulation Factors; D016682:Lupus Coagulation Inhibitor; D005169:Factor VIII